Global Liquid Biopsy Market Outlook to 2023
With constant advancements in medical field in respect of technology and treatments, cancer tests have become more personalised and advanced. A similar boom is underway to speed up and improve the detection of cancers, known as Liquid Biopsy, an emerging group of technologies which holds the promise to revolutionize cancer diagnostics and treatment. Its wide applicability has sparked off a lot of interest among researchers and commercial players.
According to RNCOS’ new research report “Global Liquid Biopsy Market Outlook to 2023”, the global liquid biopsy market is projected to cross the US$ 5 Billion mark by the end of 2023. A number of factors such as growing public and private funding to support research activities in the field of liquid biopsy, rising preference by oncologists for liquid biopsy, growing number of product launches to support development and increasing adoption of personalised medicine is driving the growth of this market.
In this report, a major focus has been on the development of innovative products based on different application, technology and different sample types. In this context, the study provides present and future outlooks for the two broad categories of liquid biopsy market; by analyte and by sample type. The former comprises of the three marker categories that dominate liquid biopsy today: circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), and extracellular vesicles (or exosomes). On the other hand, the latter includes the two major bodily fluid samples: blood and urine. According to report, blood is the most widely used sample type and is expected to remain the largest market based on sample type in the coming years as well.
The report also includes a detailed analysis of commercialized liquid biopsy products. A handful of companies are currently marketing liquid biopsies, but commercial applications remain largely limited to therapy selection, and treatment monitoring. A detailed pipeline analysis of upcoming liquid biopsy products has also been conducted. Most of the current research is focused on utilizing liquid biopsy for diagnostic purposes such as response evaluation, expression profiling, tumor diagnosis, and treatment monitoring in a blood test.
The market has been divided into four major geographic regions: North America, Europe, Asia, and Rest of the World. North America is the largest market for the liquid biopsy industry. This high share is attributed to the relatively high adoption rate of liquid biopsy coupled with launch of new and advanced products in the market. The Asian market is poised to witness the highest growth owing to increasing focus of players in this region.
RNCOS, in its report, further covers how major trends and drivers, mainly therapy selection, increasing use of circulating tumor cells for cancer screening, growing interest of venture capital firms etc., will propel the industry’s growth. An analysis has also been done of a few factors limiting the growth of the industry.
After an exhaustive study of the industry, RNCOS has laid out the primary market players that are engaged in providing liquid biopsy–based tools and services. These players are working over a vast variety of products such as blood-based tests, urine-based tests, assays and instruments for sample extraction, amplification and purification, and constantly upgrading their portfolio to keep up with the latest developments in the field. Some of these players include QIAGEN NV, Roche Diagnostics, Foundation Medicine, Trovagene, Guardant Health, and Biocept.
Overall, even though the market is in its nascent stage at the moment, it is expanding at an almost exponential rate. With new players entering the market, increase in the number of collaborations and strong support from research institutes, the liquid biopsy market is bound to witness rampant diversification and growth in the coming years.
According to RNCOS’ new research report “Global Liquid Biopsy Market Outlook to 2023”, the global liquid biopsy market is projected to cross the US$ 5 Billion mark by the end of 2023. A number of factors such as growing public and private funding to support research activities in the field of liquid biopsy, rising preference by oncologists for liquid biopsy, growing number of product launches to support development and increasing adoption of personalised medicine is driving the growth of this market.
In this report, a major focus has been on the development of innovative products based on different application, technology and different sample types. In this context, the study provides present and future outlooks for the two broad categories of liquid biopsy market; by analyte and by sample type. The former comprises of the three marker categories that dominate liquid biopsy today: circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), and extracellular vesicles (or exosomes). On the other hand, the latter includes the two major bodily fluid samples: blood and urine. According to report, blood is the most widely used sample type and is expected to remain the largest market based on sample type in the coming years as well.
The report also includes a detailed analysis of commercialized liquid biopsy products. A handful of companies are currently marketing liquid biopsies, but commercial applications remain largely limited to therapy selection, and treatment monitoring. A detailed pipeline analysis of upcoming liquid biopsy products has also been conducted. Most of the current research is focused on utilizing liquid biopsy for diagnostic purposes such as response evaluation, expression profiling, tumor diagnosis, and treatment monitoring in a blood test.
The market has been divided into four major geographic regions: North America, Europe, Asia, and Rest of the World. North America is the largest market for the liquid biopsy industry. This high share is attributed to the relatively high adoption rate of liquid biopsy coupled with launch of new and advanced products in the market. The Asian market is poised to witness the highest growth owing to increasing focus of players in this region.
RNCOS, in its report, further covers how major trends and drivers, mainly therapy selection, increasing use of circulating tumor cells for cancer screening, growing interest of venture capital firms etc., will propel the industry’s growth. An analysis has also been done of a few factors limiting the growth of the industry.
After an exhaustive study of the industry, RNCOS has laid out the primary market players that are engaged in providing liquid biopsy–based tools and services. These players are working over a vast variety of products such as blood-based tests, urine-based tests, assays and instruments for sample extraction, amplification and purification, and constantly upgrading their portfolio to keep up with the latest developments in the field. Some of these players include QIAGEN NV, Roche Diagnostics, Foundation Medicine, Trovagene, Guardant Health, and Biocept.
Overall, even though the market is in its nascent stage at the moment, it is expanding at an almost exponential rate. With new players entering the market, increase in the number of collaborations and strong support from research institutes, the liquid biopsy market is bound to witness rampant diversification and growth in the coming years.
1. ANALYST VIEW
2. RESEARCH METHODOLOGY
3. LIQUID BIOPSY: AN INTRODUCTION
4. MARKET DYNAMICS
4.1 Market Drivers
4.1.1 High Prevalence of Cancer
4.1.2 Technological Advancements in Personalized Therapies
4.1.3 Increasing Demand for Minimally Invasive Biopsy Techniques
4.1.4 Low Cost
4.1.5 Growing Interest of Venture Capital Firms
4.2 Market Restraints
4.2.1 A Less-Defined Regulatory Environment
4.2.2 Comparatively Low Concentration of Molecular Biomarkers in Body Fluids
4.2.3 Need for Proper Handling and Storage of the Samples
4.3 Market Opportunities
4.3.1 Use of Urine Sample May Witness a Paradigm Shift in Screening and Monitoring Practices
4.3.2 Exosomes Offer Great Advantages as Source Materials
4.3.3 Next-Generation Sequencing Offers Significant Opportunity
4.3.4 Prenatal Screening and Organ Transplantation: Upcoming Applications
4.4 Industry Trends
4.4.1 Circulating Tumor Cells: Gaining Potential in Liquid Biopsy
4.4.2 Blood: The Most Widely Used Sample
5. GLOBAL LIQUID BIOPSY MARKET OUTLOOK TO 2023
6. COMMERCIALLY DEVELOPED LIQUID BIOPSY TESTS
7. GLOBAL LIQUID BIOPSY MARKET SIZE BY TECHNOLOGY
7.1 Circulating Tumor Cells (CTCs)
7.2 Circulating Tumor DNA (ctDNA)
7.3 Exosomes
8. GLOBAL LIQUID BIOPSY MARKET SIZE BY SAMPLE TYPE
8.1 Blood
8.2 Urine
8.3 Other Fluids
9. GLOBAL LIQUID BIOPSY MARKET SIZE BY GEOGRAPHY
9.1 North America
9.2 Europe
9.3 Asia
9.4 Rest of the World (RoW)
10. PIPELINE ANALYSIS
11. KEY PLAYER ANALYSIS
11.1 Personal Genome Diagnostics
11.2 Guardant Health, Inc.
11.3 Pathway Genomics
11.4 RainDance Technologies
11.5 Trovagene, Inc.
11.6 Cynvenio Biosystems, Inc.
11.7 Biocept, Inc.
11.8 ANGLE plc
11.9 MDxHealth
11.10 Clearbridge BioMedics Pte Ltd
11.11 Exosome Diagnostics, Inc.
11.12 Foundation Medicine, Inc.
11.13 Roche Diagnostics (A Subsidiary of F. Hoffmann-La Roche AG)
11.14 Genomic Health
11.15 Myriad Genetics, Inc.
11.16 Thermo Fisher Scientific, Inc.
11.17 QIAGEN NV
11.18 Bio-Rad Laboratories, Inc.
12. THE FUTURE OF LIQUID BIOPSY
2. RESEARCH METHODOLOGY
3. LIQUID BIOPSY: AN INTRODUCTION
4. MARKET DYNAMICS
4.1 Market Drivers
4.1.1 High Prevalence of Cancer
4.1.2 Technological Advancements in Personalized Therapies
4.1.3 Increasing Demand for Minimally Invasive Biopsy Techniques
4.1.4 Low Cost
4.1.5 Growing Interest of Venture Capital Firms
4.2 Market Restraints
4.2.1 A Less-Defined Regulatory Environment
4.2.2 Comparatively Low Concentration of Molecular Biomarkers in Body Fluids
4.2.3 Need for Proper Handling and Storage of the Samples
4.3 Market Opportunities
4.3.1 Use of Urine Sample May Witness a Paradigm Shift in Screening and Monitoring Practices
4.3.2 Exosomes Offer Great Advantages as Source Materials
4.3.3 Next-Generation Sequencing Offers Significant Opportunity
4.3.4 Prenatal Screening and Organ Transplantation: Upcoming Applications
4.4 Industry Trends
4.4.1 Circulating Tumor Cells: Gaining Potential in Liquid Biopsy
4.4.2 Blood: The Most Widely Used Sample
5. GLOBAL LIQUID BIOPSY MARKET OUTLOOK TO 2023
6. COMMERCIALLY DEVELOPED LIQUID BIOPSY TESTS
7. GLOBAL LIQUID BIOPSY MARKET SIZE BY TECHNOLOGY
7.1 Circulating Tumor Cells (CTCs)
7.2 Circulating Tumor DNA (ctDNA)
7.3 Exosomes
8. GLOBAL LIQUID BIOPSY MARKET SIZE BY SAMPLE TYPE
8.1 Blood
8.2 Urine
8.3 Other Fluids
9. GLOBAL LIQUID BIOPSY MARKET SIZE BY GEOGRAPHY
9.1 North America
9.2 Europe
9.3 Asia
9.4 Rest of the World (RoW)
10. PIPELINE ANALYSIS
11. KEY PLAYER ANALYSIS
11.1 Personal Genome Diagnostics
11.2 Guardant Health, Inc.
11.3 Pathway Genomics
11.4 RainDance Technologies
11.5 Trovagene, Inc.
11.6 Cynvenio Biosystems, Inc.
11.7 Biocept, Inc.
11.8 ANGLE plc
11.9 MDxHealth
11.10 Clearbridge BioMedics Pte Ltd
11.11 Exosome Diagnostics, Inc.
11.12 Foundation Medicine, Inc.
11.13 Roche Diagnostics (A Subsidiary of F. Hoffmann-La Roche AG)
11.14 Genomic Health
11.15 Myriad Genetics, Inc.
11.16 Thermo Fisher Scientific, Inc.
11.17 QIAGEN NV
11.18 Bio-Rad Laboratories, Inc.
12. THE FUTURE OF LIQUID BIOPSY
LIST OF FIGURES:
Figure 4-1: Global - Cancer Incidence by Type (Million), 2025
Figure 4-2: Comparison of the analysis capability of CTC’s, cfDNA, and exosomes
Figure 5-1: Global - Liquid Biopsy Market (Million US$), 2017 & 2023
Figure 6-1: Major Trends in Commercialized Liquid Biopsy Products
Figure 7-1: Global - Liquid Biopsy Market by Technology (%), 2017
Figure 7-2: Global - Liquid Biopsy Market for CTCs (Million US$), 2017 & 2023
Figure 7-3: Global - Liquid Biopsy Market for ctDNA (Million US$), 2017 & 2023
Figure 7-4: Global - Liquid Biopsy Market for Exosomes (Million US$), 2017 & 2023
Figure 8-1: Global - Liquid Biopsy Market by Sample Type (%), 2017
Figure 8-2: Global - Blood Based Liquid Biopsy Market (Million US$), 2017 & 2023
Figure 8-3: Global - Urine Based Liquid Biopsy Market (Million US$), 2017 & 2023
Figure 8-4: Global - Other Fluids Based Liquid Biopsy Market (Million US$), 2017 & 2023
Figure 9-1: Global - Liquid Biopsy Market by Geography (%), 2017
Figure 9-2: North America - Cancer Incidences by Type (‘000), 2015 & 2025
Figure 9-3: North America - Liquid Biopsy Market (Million US$), 2017 & 2023
Figure 9-4: Europe - Cancer Incidences by Type (‘000), 2015 & 2025
Figure 9-5: Europe - Liquid Biopsy Market (Million US$), 2017 & 2023
Figure 9-6: Asia - Cancer Incidences by Type (‘000), 2015 & 2025
Figure 9-7: Asia - Liquid Biopsy Market (Million US$), 2017 & 2023
Figure 9-8: Rest of the World - Liquid Biopsy Market (Million US$), 2017 & 2023
Figure 10-1: Pipeline Analysis for Liquid Biopsy
Figure 11-1: Roche Diagnostics - Revenue by Segment (%), 2016
Figure 11-2: Myriad Genetics - Revenue by Segment (%), 2016
Figure 11-3:Thermo Fisher Scientific, Inc. - Revenue by Segment (%), 2016
Figure 11-4: Thermo Fisher Scientific, Inc. - Revenue by Geography (%), 2016
Figure 11-5: QIAGEN NV - Net Sales by Segment (%), 2016
Figure 11-6: QIAGEN NV - Net Sales by Geography (%), 2016
Figure 4-1: Global - Cancer Incidence by Type (Million), 2025
Figure 4-2: Comparison of the analysis capability of CTC’s, cfDNA, and exosomes
Figure 5-1: Global - Liquid Biopsy Market (Million US$), 2017 & 2023
Figure 6-1: Major Trends in Commercialized Liquid Biopsy Products
Figure 7-1: Global - Liquid Biopsy Market by Technology (%), 2017
Figure 7-2: Global - Liquid Biopsy Market for CTCs (Million US$), 2017 & 2023
Figure 7-3: Global - Liquid Biopsy Market for ctDNA (Million US$), 2017 & 2023
Figure 7-4: Global - Liquid Biopsy Market for Exosomes (Million US$), 2017 & 2023
Figure 8-1: Global - Liquid Biopsy Market by Sample Type (%), 2017
Figure 8-2: Global - Blood Based Liquid Biopsy Market (Million US$), 2017 & 2023
Figure 8-3: Global - Urine Based Liquid Biopsy Market (Million US$), 2017 & 2023
Figure 8-4: Global - Other Fluids Based Liquid Biopsy Market (Million US$), 2017 & 2023
Figure 9-1: Global - Liquid Biopsy Market by Geography (%), 2017
Figure 9-2: North America - Cancer Incidences by Type (‘000), 2015 & 2025
Figure 9-3: North America - Liquid Biopsy Market (Million US$), 2017 & 2023
Figure 9-4: Europe - Cancer Incidences by Type (‘000), 2015 & 2025
Figure 9-5: Europe - Liquid Biopsy Market (Million US$), 2017 & 2023
Figure 9-6: Asia - Cancer Incidences by Type (‘000), 2015 & 2025
Figure 9-7: Asia - Liquid Biopsy Market (Million US$), 2017 & 2023
Figure 9-8: Rest of the World - Liquid Biopsy Market (Million US$), 2017 & 2023
Figure 10-1: Pipeline Analysis for Liquid Biopsy
Figure 11-1: Roche Diagnostics - Revenue by Segment (%), 2016
Figure 11-2: Myriad Genetics - Revenue by Segment (%), 2016
Figure 11-3:Thermo Fisher Scientific, Inc. - Revenue by Segment (%), 2016
Figure 11-4: Thermo Fisher Scientific, Inc. - Revenue by Geography (%), 2016
Figure 11-5: QIAGEN NV - Net Sales by Segment (%), 2016
Figure 11-6: QIAGEN NV - Net Sales by Geography (%), 2016
LIST OF TABLES:
Table 11-1: Personal Genome Diagnostics - Liquid Biopsy Associated Product Line
Table 11-2: Guardant Health - Liquid Biopsy Associated Product Line
Table 11-3: Pathway Genomics - Liquid Biopsy Associated Product Line
Table 11-4: RainDance Technologies - Liquid Biopsy Associated Product Line
Table 11-5: Trovagene, Inc. - Key Financials (Million US$), 2014-2016
Table 11-6: Trovagene, Inc. - Liquid Biopsy Associated Product Line
Table 11-7: Cynvenio Biosystems, Inc. - Liquid Biopsy Associated Product Line
Table 11-8: Biocept, Inc. - Key Financials (Million US$), 2014-2016
Table 11-9: Biocept, Inc. - Liquid Biopsy Associated Product Line
Table 11-10: ANGLE plc - Key Financials (Million US$), 2014-2016
Table 11-11: ANGLE plc - Liquid Biopsy Associated Product Line
Table 11-12: MDxHealth - Key Financials (Million US$), 2014-2016
Table 11-13: MDxHealth - Liquid Biopsy Associated Product Line
Table 11-14: Clearbridge BioMedics Pte Ltd - Liquid Biopsy Associated Product Line
Table 11-15: Exosome Diagnostics, Inc. - Liquid Biopsy Associated Product Line
Table 11-16: Foundation Medicine, Inc. - Key Financials (Million US$), 2014-2016
Table 11-17: Foundation Medicine, Inc. - Liquid Biopsy Associated Product Line
Table 11-18: Roche Diagnostics - Net Sales (Million US$), 2014-2016
Table 11-19: Roche Diagnostics - Liquid Biopsy Associated Product Line
Table 11-20: Genomic Health - Key Financials (Million US$), 2014-2016
Table 11-21: Genomic Health - Liquid Biopsy Associated Product Line
Table 11-22: Myriad Genetics - Key Financials (Million US$), 2014-2016
Table 11-23: Myriad Genetics - Liquid Biopsy Associated Product Line
Table 11-24: Thermo Fisher Scientific, Inc. - Net Sales (Million US$), 2014-2016
Table 11-25: Thermo Fisher Scientific, Inc. - Liquid Biopsy Associated Product Line
Table 11-26: QIAGEN NV - Net Sales (Million US$), 2014-2016
Table 11-27: QIAGEN NV - Liquid Biopsy Associated Product Line
Table 11-28: Bio-Rad Laboratories, Inc. - Key Financials (Million US$), 2014-2016
Table 11-29: Bio-Rad Laboratories, Inc. - Liquid Biopsy Associated Product Line
Table 11-1: Personal Genome Diagnostics - Liquid Biopsy Associated Product Line
Table 11-2: Guardant Health - Liquid Biopsy Associated Product Line
Table 11-3: Pathway Genomics - Liquid Biopsy Associated Product Line
Table 11-4: RainDance Technologies - Liquid Biopsy Associated Product Line
Table 11-5: Trovagene, Inc. - Key Financials (Million US$), 2014-2016
Table 11-6: Trovagene, Inc. - Liquid Biopsy Associated Product Line
Table 11-7: Cynvenio Biosystems, Inc. - Liquid Biopsy Associated Product Line
Table 11-8: Biocept, Inc. - Key Financials (Million US$), 2014-2016
Table 11-9: Biocept, Inc. - Liquid Biopsy Associated Product Line
Table 11-10: ANGLE plc - Key Financials (Million US$), 2014-2016
Table 11-11: ANGLE plc - Liquid Biopsy Associated Product Line
Table 11-12: MDxHealth - Key Financials (Million US$), 2014-2016
Table 11-13: MDxHealth - Liquid Biopsy Associated Product Line
Table 11-14: Clearbridge BioMedics Pte Ltd - Liquid Biopsy Associated Product Line
Table 11-15: Exosome Diagnostics, Inc. - Liquid Biopsy Associated Product Line
Table 11-16: Foundation Medicine, Inc. - Key Financials (Million US$), 2014-2016
Table 11-17: Foundation Medicine, Inc. - Liquid Biopsy Associated Product Line
Table 11-18: Roche Diagnostics - Net Sales (Million US$), 2014-2016
Table 11-19: Roche Diagnostics - Liquid Biopsy Associated Product Line
Table 11-20: Genomic Health - Key Financials (Million US$), 2014-2016
Table 11-21: Genomic Health - Liquid Biopsy Associated Product Line
Table 11-22: Myriad Genetics - Key Financials (Million US$), 2014-2016
Table 11-23: Myriad Genetics - Liquid Biopsy Associated Product Line
Table 11-24: Thermo Fisher Scientific, Inc. - Net Sales (Million US$), 2014-2016
Table 11-25: Thermo Fisher Scientific, Inc. - Liquid Biopsy Associated Product Line
Table 11-26: QIAGEN NV - Net Sales (Million US$), 2014-2016
Table 11-27: QIAGEN NV - Liquid Biopsy Associated Product Line
Table 11-28: Bio-Rad Laboratories, Inc. - Key Financials (Million US$), 2014-2016
Table 11-29: Bio-Rad Laboratories, Inc. - Liquid Biopsy Associated Product Line
